<DOC>
	<DOCNO>NCT00443157</DOCNO>
	<brief_summary>This study third series use MenB vaccine National Institute Public Health Norway ( NIPH ) . The vaccine first make response high incidence disease use 44/76 strain resopnsible disease . The VEC first study , MNB1 , use vaccine . Since NIPH form commercial partnership Chiron Vaccines reformulate vaccine use NZ98/254 MenB strain use New Zealand . The vaccine first produce NIPH facilties vaccine use second study , MNB2 . The current study , MNB3 , use NZ98/254 MenB vaccine Chiron facility production scale order provide enough dos national immunisation campaign ongoing New Zealand .</brief_summary>
	<brief_title>Meningococcal B Vaccination University Students</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Informed write consent give four immunisation ( group 2 receive 3 dos ) MeNZB TM vaccine , well eight blood draw take described patient information leaflet appendix 2 Healthy adult ( university student ) age 18 40 year inclusion study On enrolment : Previous history bacteriologically confirm disease cause N. meningitidis Prior receipt group B meningococcal vaccine household contact and/or intimate exposure individual culture PCR proven N. meningitidis serogroup B within previous 60 day either receive , intent immunize , vaccine investigational agent within 50 day prior enrolment , 50 day follow last study vaccine administration , exception influenza vaccine postexposure tetanus vaccination history anaphylactic shock , urticaria allergic reaction previous vaccination hypersensitivity vaccine component experience significant acute chronic infection require systemic antibiotic treatment within past 14 day present suspect serious acute chronic disease : cardiac autoimmune disease , insulin dependent diabetes progressive neurological disease severe malnutrition , acute progressive hepatic disease , acute progressive renal disease ; leukaemia , lymphoma , neoplasm ; know suspect impairment immune function , receive immunosuppressive therapy , receive immunosuppressive therapy , include systemic steroid , ACTH inhale steroid dosage associate hypothalamicpituitaryadrenal axis suppression ; receive blood , blood product parenteral immunoglobulin preparation past 12 week ; know bleeding diathesis , condition may associate prolonged bleeding time ; history seizure disorder ; inherit genetic anomaly ( know cytogenic disorder ) e.g. , Down 's syndrome ; Language difficulty sufficient preclude adequate comprehension information sheet , consent form study nurse 's explanation study ; The possibility pregnancy pregnancy test ( urine ) schedule day vaccination offer female wish participate study . A positive test result exclusion study . ( Agreement female participant seek prior vaccination take adequate precaution avoid pregnancy duration vaccination phase study final blood sample appointment follow final vaccination , i.e . week 63 visit 8 blood appointment ) ; Current regimen chronic prescription medication oral contraceptive , current regular use overthecounter concomitant medication include antipyretic nonsteroidal antiinflammatory agent ; Current participation clinical trial ( undertake seek participant enrol clinical trial duration study ) ; They condition , opinion investigator , might interfere evaluation study objective Current ( checked prior vaccination ) : Generalised acute systemic illness day immunisation Sublingual temperature &gt; 38,5oC day immunisation Development condition specify initial exclusion criterion cite constitute criterion exclusion receive subsequent vaccine dos . Any serious reaction relate study vaccine , opinion investigator alter course subsequent study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>meningococcal B vaccine</keyword>
</DOC>